The verified answer
As of Oct 2026, DEPLOY verifies Omnicell: 1 model, $56.0M raised, 1 active incident. 3 sources back the record.
CategoryIndustrial Robots
Appears inManufacturing robots
Overview
Omnicell, Inc. (NASDAQ: OMCL) is an American healthcare technology company specializing in medication management automation. Founded in 1992 by Randall Lipps and headquartered in Cranberry Township, Pennsylvania, Omnicell provides the XR2 Automated Central Pharmacy System, automated dispensing cabinets, and IV compounding robots to hospitals and health systems. The company reported $1.185 billion in revenue for fiscal year 2025 and serves thousands of hospitals and pharmacies across North America.
Verified record
- Verified deployments
- None on file
- Active incidents
- 1 incident on file
Valuation of record
DEPLOY VERIFIEDPriced roundIPO post-money
Key facts
Revenue
Clients
Product portfolio
Data & sources
Press releases
2
Research
1
3 sources backing this record.View all →
Models (1)
View all models →Omnicell on the deployment map
View the global mapOmnicell has no verified deployments on the DEPLOY registry yet. Explore the deployment map by place and type.
No verified deployments for Omnicell on the DEPLOY record yet. Track Omnicell to know the moment the first one is verified.
Relationships
Current leadership (1)
- Randall Lipps Founder, Chairman & CEOsecondary-verified
Founders (2)
- Randall Lippssole
- Randall Lippsno longer at company
Safety record
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Incidents affecting Omnicell (1)
Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.
Recent coverage
Omnicell in third-party press
Peers
75 peers across 1 segment. Every Omnicell competitor derived from shared form-factor and application-domain edges.
industrial robot(75)
33 companies in this segment · moderately_concentrated (HHI 2051.61304640928) · leader Mind Robotics at 3415%
- ABB Roboticsdirect competitor(inferred)strong
- AMP Roboticsdirect competitor(inferred)strong
- BD Rowadirect competitor(inferred)strong
- Comaudirect competitor(inferred)strong
- Diakontdirect competitor(inferred)strong
- EFORT Intelligent Equipmentdirect competitor(inferred)strong
Financial state
- Total funding
- $56.0M
- Reporting basis
- sec_10k
- Lifecycle stage
- growth
- Counterparty risk class
- moderate
Each numeric field carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.
Funding rounds (1)
- IPO2001-08-07
$56M(reported) · $560M post
Investors: NASDAQ (public market) (lead)
Timeline
Every recorded move in Omnicell’s history, most recent first: funding rounds, partnerships, acquisitions, supply-chain starts, key hires, and press.
Funding roundIPO funding round
2001-08-07IPO raising $56000000
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Record createdJun 24, 2026
Added to the verified registry
- Incident recordedApr 10, 2026
FDA Class I Recall: Omnicell i.v.STATION syringe labels may cause mislabeled sterile...
Sources (3)
- https://www.omnicell.com/central-pharmacy/xr2/
- Omnicell: Official Website · https://www.omnicell.com/
- Omnicell Announces Fiscal Year and Fourth Quarter 2025 Financial Results · https://ir.omnicell.com/news/news-details/2026/Omnicell-Announces-Fiscal-Year-and-Fourth-Quarter-2025-Financial-Results/default.aspx
Common questions
What is Omnicell?
What does Omnicell make?
Who competes with Omnicell?
Who is the CEO of Omnicell?
Where is Omnicell headquartered?
How much funding has Omnicell raised?
Where does Omnicell operate robots?
Is Omnicell a top robotics company?
When was Omnicell founded?
Are there any incidents involving Omnicell?
Is Omnicell safe?
Methodology: Verified · 3 sources (3 primary) · last reviewed 2026-08-21
Verification posture
Verified
High confidence
Review state
Stable
Last reviewed 2026-08-21
Sources by quality tier
- 2
- primary-company-ir
- Company IR disclosure
- 1
- primary-academic-peer-reviewed
- Peer-reviewed clinical / academic
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Omnicell.Peer companies
- Savoye5 models
- Ambi Robotics2 models
- DENSO Corporation2 models
- FANUC Corporation2 models
- KUKA AG2 models
- Mitsubishi Electric FA2 models
In the press
Recent coverage mentioning Omnicell from third-party publications. Automatically surfaced; not part of the verified registry record.
FDA Class I Recall: Omnicell Removes Syringe Labels Used with i.v.STATION Automated Compounding System
FDA classified as Class I recall after Omnicell identified inconsistent label detection behavior in i.v.STATION printers that could result in unlabeled or mislabeled sterile…
Omnicell Announces Fiscal Year and Fourth Quarter 2025 Financial Results
Omnicell reported total revenue of .185 billion for fiscal year 2025, up 7% from 2024, driven by growth in its pharmacy automation systems.
Omnicell Acquires Certain Assets of ReCept Specialty Pharmacy
Omnicell announced the strategic acquisition of ReCept Specialty Pharmacy assets to support its Autonomous Pharmacy vision and expand specialty pharmacy management services.
XR2 Automated Central Pharmacy System
The XR2 system is an advanced robot that automates critical pharmacy workflows to maximize inventory control, designed with input from leading health system pharmacies.
Machine-readable surfaces
- Markdown mirror: /companies/omnicell.md
- RSS feed: /companies/omnicell/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/4b4def26-5306-4c0c-a4a8-a3672c7faf56
- Revision history: /companies/omnicell/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Peer companies
- Savoye5 models
- Ambi Robotics2 models
- DENSO Corporation2 models
- FANUC Corporation2 models
- KUKA AG2 models
- Mitsubishi Electric FA2 models
Video
BBC Breakfast News reports how Omnicell automated dispensing systems and robotic dispensing solution are automating NHS drug prescriptions at Isle of Wight NHS
This is a demonstration on how to remove expired meds from the Omnicell. Steps that are not shown: 1. Once the bin is selected enter the number of items within
The Omnicell XR2 Automated Central Pharmacy System prepares and organizes medications behind-the-scenes, giving our team more time to focus on direct patient ca
SAW Tech enabled MultiMed Blister Packaging automation with integrated vision system that checks pills as they are dropped into the blister.
In a state-of-the-art innovation lab in Austin, Omnicell is developing and deploying what it calls the pharmacy of the future—a system that seamlessly manages m
A comprehensive robotic dispensing solution MedPick brings together Gollmann’s advanced robotic dispensing technology and Omnicell’s HubXpert pharmacy orchestr
Heat Index
Category contender75/100
A composite of competitive footprint, funding, press velocity, active partnerships, and supply-chain edges. Different from the Intelligence score below (which is per-form-factor productization). Non-robotics companies cap at 25.
Reality vs attention
Omnicell draws attention at the 20th percentile but verifies reality at the insufficient-data level among industrial_robot robots.
6-month trend
Analysis
Safety profile within acceptable range for category. Limited public visibility and press coverage relative to peers.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Oct 3, 2026